On March 26, 2026, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, Stock Code: 688319) and Westlake University officially signed a cooperation agreement. Following multiple on-site inspections and in-
Recently, the China National Intellectual Property Administration issued the Notice on Determining the Demonstration Creation Objects for the Construction of a National Intellectual Property Powerhouse (2025-2027). Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was successfully selected as a “National Intellectual Property Demonstration Enterprise Creation Object” by virtue of its systematic layout and outstanding achievements in the comprehensive management of in

Recently, Sichuan Institute of Industry and Information Technology announced the List of Top 100 Enterprises of New Economy in Sichuan Province in 2022. OLYMVAX was successfully included in the list and ranked 11th.

Mr. Liu Jian, Deputy Director General of the Department of International Cooperation of China National Intellectual Property Administration, visited OLYMVAX for investigation and guidance...

On December 15, 2022, the OLYMVAX Research Institute was completed and started business in Chengdu Tianfu International Bio-town, serving as a powerful engine for vaccine research and development! A group of leaders attended the inauguration ceremony of OLYMVAX Research Institute to witness this important development milestone of OLYMVAX, including Fan Shaowen...

On October 13, Shanghai Stock Exchange and China Securities Index Co., Ltd. officially announced the release arrangement of the SSE STAR Growth Index (referred to as STAR Growth). As one of two selected enterprises in Sichuan,...

Recently, the China National Intellectual Property Administration publicized the evaluation results of the 2022 National Enterprises with Advantage in IPRs and Demonstration Enterprises,...